StockNews.AI
AZN
StockNews.AI
21 days

AstraZeneca results: H1 and Q2 2025

1. AstraZeneca reports strong revenue growth for H1 2025, boosting EPS significantly. 2. Product sales increased by 10% in Q2 2025, indicating growing demand.

Earnings
+6.28%Current Return
VS
-0.05%S&P 500
$71.8307/29 07:28 AM EDTEvent Start
$76.3407/30 02:13 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

These strong revenue and EPS results signal strong market performance. Historical similar earnings announcements often lead to sustained price increases.

How important is it?

Strong earnings and sales growth directly correlate with investor confidence, likely influencing AZN's stock prices positively.

Why Short Term?

Immediate boost in stock price expected post-earnings report, as seen historically. Strong quarterly results typically lead to positive investor sentiment and buying behavior.

Related Companies

PFEMRKJNJ
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11 Reported EPS ($) 3.46 31 32 1.58 27 31 Core3 EPS ($) 4.66 16 17 2.17 10 12 Key performance elements for H1 2025 (Growth numbers at constant exchange.

Related News